- The FDA clears Genzyme's (SNY -0.3%) Cerdelga (eliglustat) an oral therapy for the treatment of adult patients with Type 1 Gaucher disease, a rare genetic disorder caused by the underproduction of the enzyme glucocerebrosidase. The enzyme deficiency causes fatty materials to accumulate in the spleen, liver and bone marrow. The drug's mechanism of action slows down the production of the fatty materials by inhibiting the metabolic process that forms them.
- Genzyme's first drug for Type 1 Gaucher disease was Ceredase (alglucerase injection) which was approved on March 11, 1985.